Dr. Levy on the Treatment of T790M-Mutant Lung Cancer
Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.
Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.
According to Levy, patients who progress on first- or second-generation tyrosine kinase inhibitors (TKIs) should be tested for T790M. T790M can be tested in blood and tissue but data suggest that the physician should start with a blood test.
If the patient is positive for T790M, osimertinib (Tagrisso) is approved for the treatment of those patients, says Levy.
